Equipotent doses of daunorubicin and idarubicin for AML: a meta-analysis of clinical trials versus in vitro estimation
- 45 Downloads
In the treatment of acute myeloid leukemia (AML), the “7 + 3”-based strategy, combining cytarabine 100–200 mg/m2 for 7 days with an anthracycline for 3 days, remains the standard of care for younger and medically fit patients. Daunorubicin (DNR) and idarubicin (IDA) are the two anthracyclines most commonly used. DNR and IDA are used interchangeably with different conversion factors, as there is no high-level evidence on the equipotency of these two agents for AML treatment. To determine the equipotent doses of DNR and IDA, we first systematically reviewed studies directly comparing the clinical outcomes of AML induction therapy utilizing DNR and IDA. We found 15 articles that met our inclusion criteria and compared time-to-event survival end points as well as complete remission rates post-induction. The DNR:IDA equipotency ratio was estimated at 5.90 with 95% confidence interval (CI) 1.7–20.7. To validate the estimate from our meta-analysis biologically, we conducted in vitro tests comparing anti-AML activity of DNR and IDA against six AML cell lines and two primary AML cells from patients with different cytogenetic and molecular characteristics. Based on these in vitro data, the equipotency dose ratio between DNR and IDA was 4.06 with 95% CI 3.64–4.49. Combining the estimates from the meta-analysis and the in vitro data using inverse-variance weighting, the current best estimate of the DNR:IDA equipotent ratio is 4.1 with 95% CI 3.9–4.3. This estimate, however, is largely driven by the in vitro chemo-sensitivity data. Given clinical studies demonstrating the safety of IDA at higher doses, our work implies that dose intensification of IDA could be investigated in future clinical trials in AML.
KeywordsAcute myeloid leukemia (AML) Anthracycline Daunorubicin Idarubicin Chemotherapy equipotency Meta-analysis
The work was partially funded by the NCI Grant P30CA134274 to the University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center.
SA performed the literature search, designed, created Supplementary Table 1 and Figure 1, and helped to write the manuscript. RGL and BACC performed in vitro studies and helped to write the manuscript. AD and CP provided consultation on pharmacy-related issues and helped to write the manuscript. JYL developed the second draft of the manuscript under the direction of AE. MRB helped to write the manuscript. YZ and NPA performed cytogenetic and molecular analyses. SMB developed the statistical design and performed statistical analysis and co-authored the final result section with AE. AE developed the study design, supervised data collection and all aspects of the study, helped with data analysis, coordinated different sections of the project, and wrote and revised the manuscript.
Compliance with ethical standards
Conflict of interest
The authors declare no relevant conflicts of interest.
This research does not involve human participants and/or animals.
No informed consent was needed for this research.
- 3.FDA (2017) Vyxeos (daunorubicin and cytarabine) liposome label. US Food and Drug Administration. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209401s209000lbl.pdf. Accessed 23 Dec 2018
- 4.FDA (2017) Mylotarg (gemtuzumab ozogamicin) label. US Food and Drug Administration. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/761060lbl.pdf. Accessed 23 Dec 2018
- 5.FDA (2017) Rydapt (midostaurin) label. US Food and Drug Administration. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/207997Orig207991Orig207992s207000lbl.pdf. Accessed 23 Dec 2018
- 8.Berman E, McBride M (1992) Comparative cellular pharmacology of daunorubicin and idarubicin in human multidrug-resistant leukemia cells. Blood 79(12):3267–3273Google Scholar
- 11.Children’s Oncology Group (2013) Long-term follow-up guidelines for survivors of childhood, adolescent, and young adult cancer 4. http://www.survivorshipguidelines.org/pdf/LTFUGuidelines_40.pdf. Accessed 22 Feb 2018
- 21.Eridani S, Singh AK, Slater NGP et al (1989) A phase II study of idarubicin versus daunorubicin in the treatment of acute non-lymphocytic leukaemia. Cancer J 2:296–299Google Scholar
- 22.Berman E, Heller G, Santorsa J et al (1991) Results of a randomized trial comparing idarubicin and cytosine arabinoside with daunorubicin and cytosine arabinoside in adult patients with newly diagnosed acute myelogenous leukemia. Blood 77(8):1666–1674Google Scholar
- 23.Mandelli F, Petti MC, Ardia A et al (1991) A randomised clinical trial comparing idarubicin and cytarabine to daunorubicin and cytarabine in the treatment of acute non-lymphoid leukaemia. A multicentric study from the Italian Co-operative Group GIMEMA. Eur J Cancer 27(6):750–755CrossRefGoogle Scholar
- 25.Wiernik PH, Banks PL, Case DC Jr et al (1992) Cytarabine plus idarubicin or daunorubicin as induction and consolidation therapy for previously untreated adult patients with acute myeloid leukemia. Blood 79(2):313–319Google Scholar
- 26.Masaoka T, Ogawa M, Yamada K, Kimura K, Ohashi Y (1996) A phase II comparative study of idarubicin plus cytarabine versus daunorubicin plus cytarabine in adult acute myeloid leukemia. Semin Hematol 33(4 Suppl 3):12–17Google Scholar
- 27.Reiffers J, Huguet F, Stoppa AM et al (1996) A prospective randomized trial of idarubicin vs daunorubicin in combination chemotherapy for acute myelogenous leukemia of the age group 55 to 75. Leukemia 10(3):389–395Google Scholar
- 35.Yates J, Glidewell O, Wiernik P et al (1982) Cytosine arabinoside with daunorubicin or adriamycin for therapy of acute myelocytic leukemia: a CALGB study. Blood 60(2):454–462Google Scholar
- 37.Owattanapanich W, Owattanapanich N, Kungwankiattichai S, Ungprasert P, Ruchutrakool T (2018) Efficacy and toxicity of idarubicin versus high-dose daunorubicin for induction chemotherapy in adult acute myeloid leukemia: a systematic review and meta-analysis. Clin Lymphoma Myeloma Leuk 18(12):814–821e813CrossRefGoogle Scholar
- 42.Tamura K (1996) A phase I study of idarubicin hydrochloride in patients with acute leukemia. The Idarubicin Study Group of Japan. Semin Hematol 33(4 Suppl 3):2–11Google Scholar